U.S. Stock Market Movement | Clinical-stage biotechnology company Aspen Neuroscience (ASPE.US) debuts on the U.S. stock market, with shares dropping over 17% after opening

According to Jinse Finance APP, on Friday, Aspen Neuroscience (ASPE.US) debuted on the US stock market. As of press time, the stock had fallen by more than 17%, trading at $12.345. The IPO price was $15. Aspen Neuroscience is a clinical-stage biotechnology company headquartered in San Diego, California, USA. Founded in 2018, it focuses on developing innovative therapies for neurodegenerative diseases such as Parkinson's disease using stem cell technology. The company's core product, sasineprocel (ANPD001), is a stem cell therapy cultivated from the patient’s own cells, aiming to improve motor function by replacing the damaged or lost dopamine neurons in Parkinson's disease patients with newly transplanted nerve cells. This therapy is currently in phase I/IIa clinical trials and has received Fast Track designation and Regenerative Medicine Advanced Therapy designation from the US Food and Drug Administration (FDA). The company plans to begin dosing patients in phase III clinical trials in the second half of 2027.